Zura Bio Limited (NASDAQ: ZURA) announced that its Phase 2 TibuSURE clinical trial design has been accepted for poster presentation ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE